NCT02095587View on ClinicalTrials.gov

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

October 31, 2014

Conditions
Hepatic Impairment
Interventions
DRUG

IPI-145

25 mg single oral capsule

Trial Locations (1)

33014

Miami

All Listed Sponsors
lead

SecuraBio

INDUSTRY

NCT02095587 - Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects | Biotech Hunter | Biotech Hunter